article · International Journal of Molecular Sciences
Tuberculosis (TB), caused by <i>Mycobacterium tuberculosis</i>, is an infectious disease that seriously affects human life and health. Despite centuries of efforts to control it, in recent years, the emergence of multidrug-resistant bacterial pathogens of <i>M. tuberculosis</i> due to various factors has exacerbated the disease, posing a serious threat to global health. Therefore, a new method to control <i>M. tuberculosis</i> is urgently needed. Phages, viruses that specifically infect bacteria, have emerged as potential biocontrol agents for bacterial pathogens due to their host specificity. In this study, a <i>mycobacterium</i> phage, Henu3, was isolated from soil around a hospital. The particle morphology, biological characteristics, genomics and phylogeny of Henu3 were characterized. Additionally, to explore the balance between phage resistance and stress response, phage Henu3-resistant strains 0G10 and 2E1 were screened by sequence passage and bidirectional validation methods, which significantly improved the sensitivity of phage to antibiotics (cefotaxime and kanamycin). By whole-genome re-sequencing of strains 0G10 and 2E1, 12 genes involved in cell-wall synthesis, transporter-encoded genes, two-component regulatory proteins and transcriptional regulatory factor-encoded genes were found to have mutations. These results suggest that phage Henu3 has the potential to control <i>M. tuberculosis</i> pathogens, and phage Henu3 has the potential to be a new potential solution for the treatment of <i>M. tuberculosis</i> infection.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/ijms25179301
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.